| Literature DB >> 35098304 |
Giacomo Calzetti1,2,3, Chiara La Morgia4, Marco Cattaneo1,5, Arturo Carta3, Francesca Bosello6, Giulia Amore7, Michele Carbonelli7, Maria Lucia Cascavilla8, Stefano Gandolfi3, Valerio Carelli4,7, Leopold Schmetterer1,9,10,11, Hendrik P N Scholl1,2, Piero Barboni8,12.
Abstract
Purpose: The purpose of this study was to evaluate optic disk perfusion and neural retinal structure in patients with subacute Leber's hereditary optic neuropathy (LHON) and LHON carriers, as compared with healthy controls.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35098304 PMCID: PMC8802032 DOI: 10.1167/iovs.63.1.43
Source DB: PubMed Journal: Invest Ophthalmol Vis Sci ISSN: 0146-0404 Impact factor: 4.799
Figure 1.Subacute LHON. Pseudocolor LSFG maps and color fundus photographs of both eyes of one patient with LHON at baseline and follow-up visits (left and right panels, respectively). In the LSFG map, regions of higher blood flow are red and regions of lower blood flow are blue. The ellipsoids define the region of interest which was used to analyze optic nerve head (ONH) perfusion. At baseline, disease duration was 12 days and 3 months in the right eye and in the left eye, respectively. The follow-up visit was undertaken 5 months later. Note the different ONH pseudocolor at the follow-up visit, indicating a decrease in ONH perfusion as compared to the baseline visit.
Demographics and Mutations of Included Carriers and Affected Patients
| ID | Sex | Age at Baseline | Condition | Gene | Mutation |
|---|---|---|---|---|---|
| C1 | M | 13 | Carrier | MT-ND4 | m.11778G>A |
| C2 | M | 13 | Carrier | MT-ND4 | m.11778G>A |
| C3 | M | 18 | Carrier | MT-ND4 | m.11778G>A |
| C4 | M | 18 | Carrier | MT-ND4 | m.11778G>A |
| C5 | M | 21 | Carrier | MT-ND1 | m.3460G>A |
| C6 | F | 29 | Carrier | MT-ND4 | m.11778G>A |
| C7 | F | 48 | Carrier | MT-ND4 | m.11778G>A |
| C8 | F | 50 | Carrier | MT-ND4 | m.11778G>A |
| C9 | F | 53 | Carrier | MT-ND4 | m.11778G>A |
| C10 | F | 60 | Carrier | MT-ND6 | m.14484T>C |
| P1 | M | 15 | Affected patient | MT-ND4 | m.11778G>A |
| P2 | M | 15 | Affected patient | MT-ND4L | m.10663T>C |
| P5 | M | 17 | Affected patient | MT-ND4 | m.11778G>A |
| P4 | M | 21 | Affected patient | MT-ND1 | m.3460G>A |
| P8 | M | 26 | Affected patient | MT-ND6 | m.14484T>C |
| P3 | M | 27 | Affected patient | MT-ND4 | m.11778G>A |
| P7 | M | 31 | Affected patient | DNAJC30 | c.152A>G p.Tyr51Cys (homozygous) |
| P6 | M | 34 | Affected patient | MT-ND4 | m.11778G>A |
Characteristics of Study Participants
| Controls | Carriers | LHON Early Sub-Acute | LHON Late Sub-Acute | LHON Dynamic | LHON Chronic | |
|---|---|---|---|---|---|---|
| Subjects/eyes | 40/40 | 10/19 | 5/6 | 7/11 | 4/7 | 4/5 |
| Age, y | 28.0 [24.0, 35.0] | 25.0 [18.0, 49.5] | 17.0 [15.0, 21.0] | 26.0 [18.0, 29.0] | 24.0 [16.5, 31.7] | 21.5 [16.5, 28.0] |
| Sex = M (%) | 21 (52.5) | 5 (50.0) | 5 (100) | 5 (100) | 5 (100) | 5 (100) |
| MT (AU) | 16.8 [15.0, 19.7] | 15.1 [14.7, 19.2] | 24.7 [24.2, 25.0] | 14.3 [13.0, 16.6] | 10.7 [10.3, 11.6] | 10.8 [10.2, 11.3] |
| RNFL thickness, µm | 93.0 [88.0, 99.0] | 111.0 [95.6, 116.3] | 109.0 [107.3, 119.5] | 91.0 [77.7, 101.0] | 84.0 [69.9, 94.0] | 60.0 [54.0, 77.0] |
| GCIPL thickness, µm | 85.0 [79.0, 88.0] | 91.0 [86.5, 94.4] | 66.0 [63.0, 72.0] | 53.0 [50.7, 56] | 54.0 [50.5, 57.0] | 51.0 [46.0, 52.0] |
Continuous data are shown as median and interquartile range. Age and sex refer to subjects, whereas MT, RNFL thickness, and GCIPL thickness refer to eyes.
Abbreviations: MT, mean tissue; AU, arbitrary unit; RNFL, retinal nerve fiber layer; GCIPL, ganglion cell + inner plexiform layer.
Figure 2.Boxplots of all measurements of MT, RNFL thickness, and GCIPL thickness. In each column, the middle line represents the median, the ends of the boxes represent 25th and 75th percentiles, and the white circles are the outliers. The scale is in arbitrary units for MT and in µm for RNFL thickness and GCIPL thickness. Abbreviations: MT, mean tissue; RNFL, retinal nerve fiber layer; GCIPL, ganglion cell + inner plexiform layer.
Comparisons Between Groups
| MT | RNFL Thickness | GCIPL Thickness | |
|---|---|---|---|
| Carriers versus controls | 0.08 [−1.75 to 1.93] ( | 8.21 [1.94, 14.49] ( | 5.34 [2.23, 8.45] ( |
| LHON early acute versus controls | 8.67 [5.92, 11.62] ( | 15.19 [6.99, 23.39] ( | −17.01 [−21.12 to −12.93] ( |
| LHON late acute versus controls | −2.73 [−4.90 to −0.55] ( | −3.94 [−11.19 to 3.32] ( | −31.34 [−34.96 to −27.72] ( |
| LHON dynamic versus controls | −5.96 [−8.65 to −3.33] ( | −17.50 [−25.69 to −9.31] ( | −32.80 [−36.89 to −28.71] ( |
| LHON chronic versus controls | −6.51 [−9.57 to −3.55] ( | −25.34 [−34.01 to −16.72] ( | −35.09 [−39.42 to −30.79] ( |
Data are presented as estimates with 95% confidence intervals and P values.
Abbreviations: MT, mean tissue; RNFL, retinal nerve fiber layer; GCIPL, ganglion cell + inner plexiform layer.
* = Statistically significant.
Figure 3.Temporal evolution of MT, RNFL thickness, and GCIPL thickness according to symptomatic disease duration. Each point represents a measurement, and the straight lines connect repeated measurements of the same eye. Smoothed averages and corresponding pointwise 95% confidence intervals were obtained by local polynomial regression. Abbreviations: MT, Mean tissue; RNFL, retinal nerve fiber layer; GCIPL, ganglion cell + inner plexiform layer. Controls’ standard score = 0 corresponds to the mean value of controls.